Flurazepam
- Atc Codes:N05CD01
- CAS Codes:1172-18-5#17617-23-1
- PHARMGKB ID:1172-18-5#17617-23-1
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Inhibits
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Belgium: Staurodorm; Germany: Dalmadorm, Flurazepam, Staurodorm; Ireland: Dalmane, Dalmapam; Italy: Dalmadorm, Felison, Flunox, Valdorm; Luxembourg: Staurodorm; Malta: Dalmane; Netherlands: Dalmadorm, Flurazepam; Portugal: Dalmadorm, Morfex; Slovenia: Fluzepam; Spain: Dormodor; UK: Dalmane.
North America
Canada: Dalmane, Flurazepam, Novo-Flupam, Som Pam, Somnol; USA: Dalmane, Flurazepam.
Latin America
Brazil: Dalmadorm.
Asia
Japan: Benozil, Dalmate, Insumin, Nergart.
Drug combinations
Chemistry
Flurazepam Hydrochloride: C~21~H~23~ClFN~3~O 2HCl. Mw: 460.80. (1) 2H-1,4-Benzodiazepin-2-one, 7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-1,3-dihydro-, dihydrochloride; (2) 7-Chloro-1-[2-(diethylamino)ethyl]-5-(o-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one dihydrochloride. CAS-1172-18-5; CAS-17617-23-1 (flurazepam)(1968).
Pharmacologic Category
Anxiolytics, Sedatives, and Hypnotics; Benzodiazepines. (ATC-Code: N05CD01).
Mechanism of action
Binds to stereospecific benzodiazepine receptors on the postsynaptic GABA neuron at several sites within the CNS, including the limbic system, reticular formation. Enhancement of inhibitory effect of GABA on neuronal excitability results by increased neuronal membrane permeability to chloride ions.
Therapeutic use
Short-term treatment of insomnia. Does not have analgesic, antidepressant, or antipsychotic properties.
Pregnancy and lactiation implications
If used during the last weeks of pregnancy, potential for neonatal CNS depression. Use of flurazepam during pregnancy contraindicated.
Unlabeled use
Contraindications
Hypersensitivity to flurazepam or any component of the formulation (cross-sensitivity with other benzodiazepines may exist).
Warnings and precautions
Anterograde amnesia is possible. May cause CNS depression. Associated with hypersensitivity reactions including anaphylaxis and angioedema. Paradoxical reactions (hyperactive or aggressive behavior), reported with benzodiazepines (particularly in adolescent/pediatric or psychiatric patients). Increased risk for hazardous sleep-related activities exists. Use caution in depression, particularly if suicidal risk may be present. Potential for drug dependency exists (use with caution in history of drug abuse or acute alcoholism). Use with caution in hepatic impairment, impaired gag reflux, renal impairment, or respiratory disease. Effects with other sedative drugs or ethanol may be potentiated. Use with caution in debilitated patients, the elderly, or patients at risk of falls. Abrupt discontinuance may result in withdrawal symptoms. May cause fetal harm if administered during pregnancy. Use with caution in compromised pulmonary function. Potential increased sensitivity (increased risk of oversedation, dizziness, confusion, and/or ataxia) in geriatric patients.